Scancell (LON:SCLP) Trading 16.1% Higher – Should You Buy?

Scancell Holdings plc (LON:SCLP) shares shot up 16.1% during mid-day trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 9.84 ($0.13). 4,136,019 shares changed hands during mid-day trading, an increase of 410% from the average session volume of 810,293 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Stock Down 2.6 %

The company has a market capitalization of £105.90 million, a price-to-earnings ratio of -15.68 and a beta of 0.35. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The firm’s 50 day simple moving average is GBX 8.51 and its 200-day simple moving average is GBX 10.85.

Scancell (LON:SCLP) last issued its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. On average, sell-side analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.